<?xml version="1.0" encoding="UTF-8"?>
<!-- This is a template for a FHIR resource, and needs items (marked with "${}") replacing to make a real instance -->
<!-- The resulting instance is a Bundle of Bundles, each of which is a document (having a Composition, and supporting resources) -->
<!-- 2020-02-22 -->
<!-- This is for FHIR version R5 Preview 2 (May 2020) -->
<Bundle xmlns="http://hl7.org/fhir">
	<type value="collection"/>
	<!-- Repeat at this level per document -->
	<entry>
		<fullUrl value="urn:uuid:8823bf35-b8bd-45cf-9779-799065ba027a"/>
		<!-- Top level of each document is a also FHIR Bundle, of type "document"
		 see http://hl7.org/fhir/documents.html, http://hl7.org/fhir/bundle.html
	 	 All the other resources for this document are within this. -->
		<resource>
            <Bundle>
            	<!-- When PUTing, some servers mandate an id here to match the existing id -->
            	<id value="c4dac377-eef0-492b-b74e-2e620d7984a5"/>
				<!-- document bundles must have an identifier (bdl-9) -->
				<identifier>
					<!-- possibly different identifier types may be needed here -->
					<system value="http://ema.europa.eu/fhir/identifier/documentid"/>
					<value value="${instance.bundle[n].Identifier}"/>
				</identifier>
				<!-- fixed code -->
				<type value="document" /> 
            	<!-- document bundles must have a date (bdl-10) -->
            	<timestamp value="2021-05-04T13:13:53Z"/>
				<!-- a repeating set of entry elements, each with a FHIR resource inside -->
				<entry>
					<!-- fullUrl is mandatory for each entry in document Bundle. It is a random uuid. http://build.fhir.org/bundle.html#bundle-unique -->
					<fullUrl value="urn:uuid:8bc6c881-be3d-42bc-9d5f-2d3fc5d3bd0a"/>
					<resource>
						<!-- the first resource must be Composition (bdl-11) -->
						<!-- This is the overall document structure. -->
						<!-- see definition http://hl7.org/fhir/composition.html, and similar for other resources -->
                        <Composition>
                        	<!-- images if requied within html text of this document -->
							
							<status value="final"/>
							<!-- document type -->
							<type>
								<coding>
									<system value="http://spor.ema.europa.eu/v1/lists/100000155531"/>
									<code value="${document[n].documentTypeCode}"/>
									<display value="${document[n].documentTypeDisplay}"/>
								</coding>
							</type>
							<subject>
								<!-- links to the List resource in this bundle - local url format -->
								<reference value="[]"/> <!-- local url format -->
								<!--reference value="${instance.bundle[n].listUuid}"/--> <!-- uuid url format. Possible alternate format may be neeed -->
							</subject>
                        	<!-- mandatory date of the document -->
                        	<date value="2021-02-01"/>
							<author>
								<identifier>
									<system value="http://spor.ema.europa.eu/v1/locations" />
									<value value="" />
								</identifier>
							</author>
                        	<title value="${document[n].title}"/>
							<relatesTo>
								<code value="appends"/>
								<targetReference>
									<!-- reference to another Composition -->
									<reference value="${document[n].relatesTo}"/>
								</targetReference>
							</relatesTo>
							<!-- main sections of the document, to follow the QRD template -->
	               			
<section>
	
		
			<title value="SUMMARY OF PRODUCT CHARACTERISTICS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="TitleA"><span lang="EN-GB">SUMMARY OF PRODUCT CHARACTERISTICS</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">1.       NAME OF THE MEDICINAL PRODUCT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius 5 mg film-coated tablets</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Each tablet contains 5 mg desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">3.       PHARMACEUTICAL FORM</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Film-coated tablets</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.       CLINICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.1     Therapeutic indications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">allergic rhinitis (see section 5.1)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">urticaria (see section 5.1)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.2     Posology and method of administration</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Posology"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Adults and adolescents (12 years of age and over) </span></i></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The recommended dose of Aerius is one tablet once a day.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.</span></p><p class="MsoNormal" style="line-height:normal"><i><span lang="EN-GB"> </span></i></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Paediatric population</span></i></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).</span></p><p class="MsoNormal" style="line-height:normal"><a name="OLE_LINK2"><span lang="EN-GB"> </span></a></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The safety and efficacy of </span><span lang="EN-GB">Aerius 5 mg film-coated tablets</span><span lang="EN-GB"> in children below the age of 12</span><span lang="EN-GB"> </span><span lang="EN-GB">years have not been established.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Method of administration</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Oral use.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The dose can be taken with or without food.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.3     Contraindications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.4     Special warnings and precautions for use</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children </span><a name="_Hlk29909058"><span lang="EN-GB">(see section 4.8)</span></a><span lang="EN-GB">, being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoBodyText2"><span lang="EN-GB" style="color:windowtext">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Interaction studies have only been performed in adults.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). </span><span lang="EN-GB">However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.6     Fertility, pregnancy and lactation</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Pregnancy"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Pregnancy</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine.</span><span lang="EN-GB"> Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). </span><span lang="EN-GB">As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Breast-feeding"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Breast-feeding</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Fertility"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Fertility</span></u></p><p class="MsoCommentText" style="line-height:normal"><span lang="EN-GB" style="font-size:11.0pt">There are no data available </span><span lang="EN-GB" style="font-size:11.0pt">on male and female fertility.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.7     Effects on ability to drive and use machines</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB" style="letter-spacing:-.15pt">Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. </span><span lang="EN-GB">Patients should be informed that most people do not experience <span style="layout-grid-mode:line">drowsiness</span></span><span lang="EN-GB" style="layout-grid-mode:line">. Nevertheless, as there is individual variation in response </span><span lang="EN-GB">to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.8     Undesirable effects</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Summary of the safety profile</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">System    Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB" style="letter-spacing:-.15pt;    layout-grid-mode:line">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB" style="letter-spacing:-.15pt;    layout-grid-mode:line">Adverse reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Psychiatric   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Hallucinations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Abnormal behaviour, aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Nervous system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Headache</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Cardiac disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT   prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Gastrointestinal disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dry mouth</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Hepatobiliary disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fatigue</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">System    Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB" style="letter-spacing:-.15pt;    layout-grid-mode:line">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB" style="letter-spacing:-.15pt;    layout-grid-mode:line">Adverse reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Psychiatric   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Hallucinations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Abnormal behaviour, aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Nervous system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Headache</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Cardiac disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT   prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Gastrointestinal disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dry mouth</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Hepatobiliary disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fatigue</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Reporting of suspected adverse reactions"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Reporting of suspected adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via <span style="color:black;background:#BFBFBF">the national reporting system listed in </span></span><span lang="EN-GB"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span style="background:#BFBFBF">Appendix V</span></a></span><span lang="EN-GB">.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.9     Overdose</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Treatment</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB" style='font-family:"Arial",sans-serif'> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.       PHARMACOLOGICAL PROPERTIES</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.1     Pharmacodynamic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">Pharmacotherapeutic group: antihistamines – H<sub>1</sub> antagonist, ATC code: R06A X27</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Mechanism of action"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Mechanism of action</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H<sub>1</sub>-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H<sub>1</sub>-receptors because the substance is excluded from entry to the central nervous system.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine has demonstrated antiallergic properties from <i>in vitro </i>studies.<i> </i>These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><u><span lang="EN-GB" style="font-weight:normal"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Clinical efficacy and safety"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Clinical efficacy and safety</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In a multiple dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol. </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In patients with allergic rhinitis, Aerius was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. <span style="layout-grid-mode:line">Aerius effectively controlled symptoms for 24 hours.</span></span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line;font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 th</span><span lang="EN-GB" style="font-weight:normal">rough 17 years of age<span style="layout-grid-mode:line">.</span></span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms. </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.2     Pharmacokinetic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Absorption"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Absorption</span></u></p><p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB">Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a pharmacokinetic trial in which patient demographics were comparable to those of the general seasonal allergic rhinitis population, 4 % of the subjects achieved a higher concentration of desloratadine. This percentage may vary according to ethnic background. Maximum desloratadine concentration was about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours. The safety profile of these subjects was not different from that of the general population.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Distribution"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Distribution</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Biotransformation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Biotransformation</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 <i>in vivo,</i> and <i>in vitro</i> studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Elimination"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine.<span style="layout-grid-mode:line"> In another study, grapefruit juice had no effect on the disposition of desloratadine.</span></span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renally impaired patients</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and C<sub>max</sub>) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.3     Preclinical safety data</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.1     List of excipients</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Tablet core: calcium hydrogen phosphate dihydrate, microcrystalline cellulose, maize starch, talc. </span></p><p class="MsoBlockText" style="margin:0in;margin-bottom:.0001pt"><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'>Tablet coating: film coat (containing lactose monohydrate, hypromellose, titanium dioxide, macrogol 400, indigotin (E132)), clear coat (containing hypromellose, macrogol 400), carnauba wax, white wax.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.2     Incompatibilities</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.3     Shelf life</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">2 years</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.4     Special precautions for storage</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Do not store above 30°C. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Store in the original package.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.5     Nature and contents of container</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius is supplied in blisters comprised of laminate blister film with foil lidding.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The materials of the blister consist of a polychlorotrifluoroethylene (PCTFE)/Polyvinyl Chloride (PVC) film (product contact surface) with an aluminium foil lidding coated with a vinyl heat seal coat (product contact surface) which is heat sealed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50, 90, 100 tablets.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.6     Special precautions for disposal</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">No special requirements.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Merck Sharp &amp; Dohme B.V.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">Waarderweg 39</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">2031 BN Haarlem</span></p><p class="MsoNormal" style="line-height:normal"><span lang="DE">The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">8.       MARKETING AUTHORISATION NUMBERS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><a name="OLE_LINK9"></a><a name="OLE_LINK10"><span lang="EN-GB">EU/1/00/160/001-013</span></a></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/00/160/036</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of first authorisation: </span><span lang="EN-GB">15 January 2001</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt;letter-spacing: -.15pt">Date of latest renewal: 15 January 2006</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span></b><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><b><span lang="EN-GB">1.       NAME OF THE MEDICINAL PRODUCT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius 2.5 mg orodispersible tablets</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Each orodispersible tablet contains 2.5 mg desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">3.       PHARMACEUTICAL FORM</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Orodispersible tablet</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Light-red, flat-faced, round, speckled tablets, one side branded with “K” </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.       CLINICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.1     Therapeutic indications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius is indicated in adults, adolescents aged 12 years and older and children aged 6 – 11 years old for the relief of symptoms associated with:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">allergic rhinitis (see section 5.1)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">urticaria (see section 5.1)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.2     Posology and method of administration</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Adults and adolescents (12</span></i><span lang="EN-GB"> <i>years of age and over)</i></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The recommended dose of Aerius is two 2.5 mg orodispersible tablets placed in the mouth once a day.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.3     Contraindications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.4     Special warnings and precautions for use</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children </span><span lang="EN-GB">(see section 4.8)</span><span lang="EN-GB">, being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Aerius orodispersible tablet. Phenylalanine may be harmful for people with phenylketonuria.</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1). </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Interaction studies have only been performed in adults.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). </span><span lang="EN-GB">However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.6     Fertility, pregnancy and lactation</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Pregnancy</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine.</span><span lang="EN-GB"> Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). </span><span lang="EN-GB">As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Breast-feeding</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Fertility</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">There are no data available on male and female fertility.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.7     Effects on ability to drive and use machines</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB" style="letter-spacing:-.15pt">Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB" style="layout-grid-mode:line">P</span><span lang="EN-GB">atients should be informed that most people do not experience <span style="layout-grid-mode: line">drowsiness. Nevertheless, </span></span><span lang="EN-GB" style="layout-grid-mode:line">as there is individual variation in response </span><span lang="EN-GB">to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.8     Undesirable effects</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Summary of the safety profile</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials, desloratadine in the syrup formulation was administered to a paediatric population. The overall incidence of adverse reactions was similar between the desloratadine syrup and the placebo groups and did not differ significantly than the safety profile seen in adult patients. </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">System    Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Adverse    reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Psychiatric   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hallucinations</span></p> <p class="MsoNormal" style="line-height:normal"><span style="letter-spacing:   -.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Nervous   system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Headache</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Cardiac   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Gastrointestinal   disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dry mouth</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Hepatobiliary   disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="layout-grid-mode:line">Elevations   of liver enzymes, increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Skin and   subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Musculoskeletal   and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">General   disorders and administration site conditions</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Fatigue</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p class="MsoNormal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal"><span lang="EN-GB">Weight increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">System    Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Adverse    reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Psychiatric   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hallucinations</span></p> <p class="MsoNormal" style="line-height:normal"><span style="letter-spacing:   -.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Nervous   system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Headache</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Cardiac   disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Gastrointestinal   disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Dry mouth</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Hepatobiliary   disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="letter-spacing:-.15pt;   layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="layout-grid-mode:line">Elevations   of liver enzymes, increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Skin and   subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">Musculoskeletal   and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB">General   disorders and administration site conditions</span></b></p> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Fatigue</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p class="MsoNormal"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal"><span lang="EN-GB">Weight increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.9     Overdose</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Treatment</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.       PHARMACOLOGICAL PROPERTIES</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.1     Pharmacodynamic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharmacotherapeutic group: antihistamines – H<sub>1</sub> antagonist, ATC code: R06A X27</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Mechanism of action</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H<sub>1</sub>-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H<sub>1</sub>-receptors because the substance is excluded from entry to the central nervous system.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine has demonstrated antiallergic properties from <i>in vitro </i>studies.<i> </i>These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy and safety</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a multiple dose trial, Aerius orodispersible tablets were well tolerated.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the recommended dose, Aerius 5 mg orodispersible tablet was found to be bioequivalent to the Aerius 5 mg conventional tablet formulation of desloratadine. Therefore, the efficacy of Aerius orodispersible tablet is expected to be the same as with the Aerius tablet formulation.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a multiple dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose, ketoconazole and erythromycin interaction trials.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine does not readily penetrate the central nervous system. In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. <span style="layout-grid-mode:line">Aerius tablets effectively controlled symptoms for 24 hours.</span></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 th</span><span lang="EN-GB">rough 17 years of age.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.2     Pharmacokinetic properties </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Absorption</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations </span><span lang="EN-GB">however the safety profile of these subjects was not different from that of the general population<span style="layout-grid-mode:line">.</span></span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a C<sub>max</sub> concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Distribution</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Biotransformation</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded.<span style="layout-grid-mode:line"> </span>Desloratadine does not inhibit CYP3A4 <i>in vivo,</i> and <i>in vitro</i> studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In single-dose crossover studies of Aerius 5 mg </span><span lang="EN-GB">orodispersible tablets <span style="layout-grid-mode:line">with Aerius 5 mg conventional tablets, the formulations were bioequivalent. </span>Aerius 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Aerius orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">The presence of food prolongs T<sub>max</sub> for desloratadine from 2.5 to 4 hours and T<sub>max</sub> for 3-OH-desloratadine from 4 to 6 hours. In a separate study, grapefruit juice had no effect on the disposition of desloratadine. Water had no effect on the bioavailability of Aerius orodispersible tablets.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renally impaired patients</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and C<sub>max</sub>) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.3     Preclinical safety data</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation in unlikely to pose risk for local irritation with clinical use. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.</span></p><p class="MsoEndnoteText"><b><span lang="EN-GB" style="font-size:11.0pt"> </span></b></p><p class="MsoEndnoteText"><b><span lang="EN-GB" style="font-size:11.0pt"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.1     List of excipients</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">microcrystalline cellulose</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">pregelatinized starch</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">sodium starch glycolate</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">magnesium stearate</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">butylated methacrylate copolymer</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">crospovidone</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">sodium hydrogen carbonate </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">citric acid</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">colloidal silicon dioxide</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ferric oxide</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">mannitol</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">aspartame (E951)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">flavour Tutti-Frutti</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.2     Incompatibilities</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.3     Shelf life</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">2 years</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.4     Special precautions for storage</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Store in the original package.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.5     Nature and contents of container</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The blister materials consist of a four layer aluminum foil laminate cold form blister film and a paper backed laminated aluminum foil lidding film.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The cold form blister film is composed of polyvinyl chloride (PVC) film adhesively laminated to an oriented polyamide (OPA) film, adhesively laminated to aluminum foil, adhesively laminated to polyvinyl chloride (PVC) film.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 orodispersible tablets.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.6     Special precautions for disposal</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">No special requirements</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Merck Sharp &amp; Dohme B.V.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">Waarderweg 39</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">2031 BN Haarlem</span></p><p class="MsoNormal" style="line-height:normal"><span lang="DE">The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">8.       MARKETING AUTHORISATION NUMBERS </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/00/160/037-048</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of first authorisation: </span><span lang="EN-GB">15 January 2001</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of latest renewal: 15 January 2006</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">1.       NAME OF THE MEDICINAL PRODUCT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius 5 mg orodispersible tablets</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Each orodispersible tablet contains 5 mg desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">3.       PHARMACEUTICAL FORM</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Orodispersible tablet</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Light-red, flat-faced, round, speckled tablets, one side branded with “A” </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.       CLINICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.1     Therapeutic indications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">allergic rhinitis (see section 5.1)</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">urticaria (see section 5.1)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.2     Posology and method of administration</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Adults and adolescents (12 years of age and over)</span></i></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The recommended dose of Aerius is one 5 mg orodispersible tablet placed in the mouth once a day.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.3     Contraindications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.4     Special warnings and precautions for use</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children </span><span lang="EN-GB">(see section 4.8)</span><span lang="EN-GB">, being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">This product contains 2.9 mg of phenylalanine per 5 mg dose of Aerius orodispersible tablet. Phenylalanine may be harmful for people with phenylketonuria.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which erythromycin or ketoconazole were co-administered (see section 5.1). </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Interaction studies have only been performed in adults.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). </span><span lang="EN-GB">However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.6     Fertility, pregnancy and lactation</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Pregnancy</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine.</span><span lang="EN-GB"> Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). </span><span lang="EN-GB">As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Breast-feeding</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Fertility</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">There are no data available on male and female fertility.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.7     Effects on ability to drive and use machines</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. P</span><span lang="EN-GB">atients should be informed that most people do not experience <span style="layout-grid-mode:line">drowsiness. Nevertheless, as there is individual variation in response </span></span><span lang="EN-GB">to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.8     Undesirable effects</span></b></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Summary of the safety profile</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse reactions reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %). </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">System Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Adverse reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Psychiatric disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Hallucinations</span></p> <p class="MsoNormal" style="line-height:normal"><span style="letter-spacing:   -.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Nervous system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Headache</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Dizziness, somnolence, insomnia, psychomotor hyperactivity,   seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Cardiac disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Gastrointestinal disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Dry mouth</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Abdominal pain, nausea, vomiting, dyspepsia,   diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Hepatobiliary disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">General disorders and administration site   conditions</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Fatigue</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Hypersensitivity reactions (such as   anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p class="MsoNormal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal"><span lang="EN-GB" style="letter-spacing:-.15pt">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">System Organ Class</span></b></p> </td> <td style="width:27.92%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Frequency</span></b></p> </td> <td style="width:38.76%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Adverse reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Psychiatric disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Hallucinations</span></p> <p class="MsoNormal" style="line-height:normal"><span style="letter-spacing:   -.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Nervous system disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Headache</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Dizziness, somnolence, insomnia, psychomotor hyperactivity,   seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Cardiac disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Gastrointestinal disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Dry mouth</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Abdominal pain, nausea, vomiting, dyspepsia,   diarrhoea</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Hepatobiliary disorders</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin, hepatitis</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">General disorders and administration site   conditions</span></b></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Common</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Very rare</span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt"> </span></p> <p align="center" class="MsoNormal" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Fatigue</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Hypersensitivity reactions (such as   anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria)</span></p> <p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal"><b><span lang="EN-GB" style="letter-spacing:-.15pt">Investigations</span></b></p> </td> <td style="width:27.92%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="27%"> <p class="MsoNormal"><span lang="EN-GB" style="letter-spacing:-.15pt">Not known</span></p> </td> <td style="width:38.76%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="38%"> <p class="MsoNormal"><span lang="EN-GB" style="letter-spacing:-.15pt">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal;text-autospace:none"><u><span lang="EN-GB"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.9     Overdose</span></b></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Treatment</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Based on a multiple dose clinical trial, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.       PHARMACOLOGICAL PROPERTIES</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.1     Pharmacodynamic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharmacotherapeutic group: antihistamines – H<sub>1</sub> antagonist, ATC code: R06A X27</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Mechanism of action</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H<sub>1</sub>-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H<sub>1</sub>-receptors because the substance is excluded from entry to the central nervous system.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine has demonstrated antiallergic properties from <i>in vitro </i>studies.<i> </i>These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy and safety</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a multiple dose trial, Aerius orodispersible tablets were well tolerated.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the recommended dose, Aerius 5 mg orodispersible tablet was found to be bioequivalent to the Aerius 5 mg conventional tablet formulation of desloratadine. Therefore, the efficacy of Aerius orodispersible tablet is expected to be the same as with the Aerius tablet formulation.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a multiple-dose clinical trial, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in which desloratadine was administered at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose, ketoconazole and erythromycin interaction trials.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine does not readily penetrate the central nervous system. In clinical trials, at the recommended dose of 5 mg daily, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical pharmacology trials, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. <span style="layout-grid-mode:line">Aerius tablets effectively controlled symptoms for 24 hours.</span></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 th</span><span lang="EN-GB">rough 17 years of age<span style="layout-grid-mode:line">.</span></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of <span style="layout-grid-mode: line">symptoms. Intermittent</span> allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.2     Pharmacokinetic properties </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Absorption</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine plasma concentrations can be detected within 30 minutes of administration. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was greater among Black adults than Caucasian adults (18 % vs. 2 %) however the safety profile of these subjects was not different from that of the general population. </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a C<sub>max</sub> concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Distribution</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant medicine accumulation following once daily dosing of desloratadine (5 mg to 20 mg) for 14 days. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Biotransformation</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded.<span style="layout-grid-mode: line"> </span>Desloratadine does not inhibit CYP3A4 <i>in vivo,</i> and <i>in vitro</i> studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In single-dose crossover studies of Aerius 5 mg </span><span lang="EN-GB">orodispersible tablets <span style="layout-grid-mode:line">with Aerius </span>5 mg conventional<span style="layout-grid-mode:line"> tablets, the formulations were bioequivalent. </span></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">The presence of food prolongs T<sub>max</sub> for desloratadine from 2.5 to 4 hours and T<sub>max</sub> for 3-OH-desloratadine from 4 to 6 hours. In a separate study, grapefruit juice had no effect on the disposition of desloratadine. Water had no effect on the bioavailability of Aerius orodispersible tablets.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renally impaired patients</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and C<sub>max</sub>) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.3     Preclinical safety data</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The collective analysis of preclinical and clinical irritation studies for the orodispersible tablet indicate that this formulation is unlikely to pose risk for local irritation with clinical use. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.1     List of excipients</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">microcrystalline cellulose</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">pregelatinized starch</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">sodium starch glycolate</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">magnesium stearate</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">butylated methacrylate copolymer</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">crospovidone</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">sodium hydrogen carbonate </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">citric acid</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">colloidal silicon dioxide</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">ferric oxide</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">mannitol</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">aspartame (E951)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">flavour Tutti-Frutti</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.2     Incompatibilities</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.3     Shelf life</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">2 years</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.4     Special precautions for storage</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Store in the original package.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.5     Nature and contents of container</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">The blister materials consist of a four layer aluminum foil laminate cold form blister film and a paper backed laminated aluminum foil lidding film.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The cold form blister film is composed of polyvinyl chloride (PVC) film adhesively laminated to an oriented polyamide (OPA) film, adhesively laminated to aluminum foil, adhesively laminated to polyvinyl chloride (PVC) film.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 orodispersible tablets.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.6     Special precautions for disposal</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No special requirements</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Merck Sharp &amp; Dohme B.V.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">Waarderweg 39</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">2031 BN Haarlem</span></p><p class="MsoNormal" style="line-height:normal"><span lang="DE">The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">8.       MARKETING AUTHORISATION NUMBERS </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/00/160/049-060</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of first authorisation: </span><span lang="EN-GB">15 January 2001</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of latest renewal: 15 January 2006</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span><br clear="all" style="page-break-before:always"/>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
		
		
    	    
				
			    
						
		               
<section>
			<title value="1.       NAME OF THE MEDICINAL PRODUCT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">1.       NAME OF THE MEDICINAL PRODUCT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius 0.5 mg/ml oral solution</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="2.       QUALITATIVE AND QUANTITATIVE COMPOSITION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Each ml of oral solution contains 0.5 mg desloratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Excipient(s) with known effect:</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">This medicinal product contains 150 mg/ml of sorbitol</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">For the full list of excipients, see section 6.1.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="3.       PHARMACEUTICAL FORM"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">3.       PHARMACEUTICAL FORM</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Oral solution</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="4.       CLINICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.       CLINICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="4.1     Therapeutic indications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.1     Therapeutic indications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius is indicated in adults, adolescents and children over the age of 1 year for the relief of symptoms associated with:</span></p><p class="MsoNormal" style="margin-left:28.5pt;text-indent:-28.5pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">allergic rhinitis (see section 5.1)</span></p><p class="MsoNormal" style="margin-left:28.5pt;text-indent:-28.5pt;line-height: normal"><span lang="EN-GB">-<span style='font:7.0pt "Times New Roman"'> </span></span><span lang="EN-GB">urticaria (see section 5.1)</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.2     Posology and method of administration"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.2     Posology and method of administration</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Posology</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><i><span lang="EN-GB">Adults and adolescents (12</span></i><span lang="EN-GB"> <i>years of age and over)</i></span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The recommended dose of Aerius is 10 ml (5 mg) oral solution once a day.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.3     Contraindications"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.3     Contraindications</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.4     Special warnings and precautions for use"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.4     Special warnings and precautions for use</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoEndnoteText" style="page-break-after:avoid"><u><span lang="EN-GB" style="font-size:11.0pt">Paediatric population</span></u></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt">In children below 2 years of age, the diagnosis of allergic rhinitis is particularly difficult to distinguish from other forms of rhinitis. The absence of upper respiratory tract infection or structural abnormalities, as well as patient history, physical examinations, and appropriate laboratory and skin tests should be considered.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Approximately 6 % of adults and children 2- to 11-year old are phenotypic poor metabolisers of desloratadine and exhibit a higher exposure (see section 5.2). The safety of desloratadine in children 2- to 11-years of age who are poor metabolisers is the same as in children who are normal metabolisers. The effects of desloratadine in poor metabolisers &lt; 2 years of age have not been studied.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In the case of severe renal insufficiency, Aerius should be used with caution (see section 5.2).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">This medicinal product contains sorbitol; thus, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.5     Interaction with other medicinal products and other forms of interaction"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.5     Interaction with other medicinal products and other forms of interaction</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No clinically relevant interactions were observed in clinical trials with desloratadine tablets in which </span><span lang="EN-GB">erythromycin or ketoconazole were co-administered (see section 5.1).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Interaction studies have only been performed in adults.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical pharmacology trial, Aerius tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). </span><span lang="EN-GB">However, cases of alcohol intolerance and intoxication have been reported during post‑marketing use. Therefore, caution is recommended if alcohol is taken concomitantly.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.6     Fertility, pregnancy and lactation"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.6     Fertility, pregnancy and lactation</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Pregnancy</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foeto/ neonatal toxicity of desloratadine.</span><span lang="EN-GB"> Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). </span><span lang="EN-GB">As a precautionary measure, it is preferable to avoid the use of Aerius during pregnancy.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Breast-feeding</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine has been identified in breastfed newborns/infants of treated women. The effect of desloratadine on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Aerius therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Fertility</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">There are no data available </span><span lang="EN-GB">on male and female fertility.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.7     Effects on ability to drive and use machines"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.7     Effects on ability to drive and use machines</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB" style="letter-spacing:-.15pt">Aerius has no or negligible influence on the ability to drive and use machines based on clinical trials. </span><span lang="EN-GB">Patients should be informed that most people do not experience drowsiness.<span style="layout-grid-mode:line"> Nevertheless, as there is individual variation in response </span></span><span lang="EN-GB">to all medicinal products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.8     Undesirable effects"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.8     Undesirable effects</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Summary of the safety profile</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal"><span style="text-decoration:none"> </span></span></u></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for the desloratadine and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse reactions reported in excess of placebo were diarrhoea (3.7 %), fever (2.3 %) and insomnia (2.3 %). In an additional study, no adverse events were seen in subjects between 6 and 11 years of age following a single 2.5 mg dose of desloratadine oral solution.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Adults and adolescents</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Aerius were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid;height:6.5pt"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">System Organ Class</span></b></p> </td> <td style="width:25.02%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Frequency</span></b></p> </td> <td style="width:41.66%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Adverse    reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Psychiatric disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hallucinations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span style="letter-spacing:-.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Nervous system disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Headache</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Insomnia</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Cardiac disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT   prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Gastrointestinal disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dry mouth</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Diarrhoea</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea </span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Hepatobiliary disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin,<span style="letter-spacing:-.15pt"> hepatitis</span></span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fatigue</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fever</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical trials in a paediatric population, the desloratadine syrup formulation was administered to a total of 246 children aged 6 months through 11 years. The overall incidence of adverse events in children 2 through 11 years of age was similar for the desloratadine and the placebo groups. In infants and toddlers aged 6 to 23 months, the most frequent adverse reactions reported in excess of placebo were diarrhoea (3.7 %), fever (2.3 %) and insomnia (2.3 %). In an additional study, no adverse events were seen in subjects between 6 and 11 years of age following a single 2.5 mg dose of desloratadine oral solution.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated</span><span lang="EN-GB"> with desloratadine and 6.9 % of patients receiving placebo.</span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Adults and adolescents</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Aerius were reported in 3 % of patients in excess of those treated with placebo. The most frequent of adverse events reported in excess of placebo were fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Tabulated list of adverse reactions</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The frequency of the clinical trial adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. </span><span lang="EN-GB">Frequencies are defined as </span><span lang="EN-GB">very common (≥ 1/10), </span><span lang="EN-GB">common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</span></p><p class="MsoNormal" style="line-height:normal"><b><span lang="EN-GB"> </span></b></p><table border="1" cellpadding="0" cellspacing="0" class="MsoNormalTable" style="width:100.0%;border-collapse:collapse;border:none" width="100%"> <thead> <tr style="page-break-inside:avoid;height:6.5pt"> <td style="width:33.32%;border:solid windowtext 1.0pt;    padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;    page-break-after:avoid"><b><span lang="EN-GB">System Organ Class</span></b></p> </td> <td style="width:25.02%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Frequency</span></b></p> </td> <td style="width:41.66%;border:solid windowtext 1.0pt;    border-left:none;padding:0in 5.4pt 0in 5.4pt;height:6.5pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Adverse    reactions seen with Aerius</span></b></p> </td> </tr> </thead> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p class="MsoNormal" style="page-break-after:avoid"><b><span lang="EN-GB">Metabolism   and nutrition disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal;   page-break-after:avoid"><span lang="EN-GB">Increased appetite</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Psychiatric disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hallucinations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span style="letter-spacing:-.15pt;layout-grid-mode:line">Abnormal behaviour,</span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black'> </span><span style="letter-spacing:-.15pt;layout-grid-mode:line">aggression</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Nervous system disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB"> </span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Headache</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Insomnia</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dizziness,   somnolence, insomnia, psychomotor hyperactivity, seizures</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Cardiac disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Tachycardia,   palpitations</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">QT   prolongation</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Gastrointestinal disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Dry mouth</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Diarrhoea</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Abdominal   pain, nausea, vomiting, dyspepsia, diarrhoea </span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Hepatobiliary disorders</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Elevations of liver enzymes,   increased bilirubin,<span style="letter-spacing:-.15pt"> hepatitis</span></span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Jaundice</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Skin and subcutaneous tissue disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Photosensitivity</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Musculoskeletal and connective tissue disorders</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB">Myalgia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">General disorders and administration site conditions</span></b></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB"> </span></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Common   (children less than 2 years)</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Very rare</span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fatigue</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Fever</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line"> </span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Hypersensitivity   reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and   urticaria)</span></p> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Asthenia</span></p> </td> </tr> <tr style="page-break-inside:avoid"> <td style="width:33.32%;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt" valign="top" width="33%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><b><span lang="EN-GB">Investigations</span></b></p> </td> <td style="width:25.02%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="25%"> <p align="center" class="MsoBodyText" style="text-align:center;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Not known</span></p> </td> <td style="width:41.66%;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt" valign="top" width="41%"> <p align="left" class="MsoBodyText" style="text-align:left;line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt;layout-grid-mode:line">Weight   increased</span></p> </td> </tr> </table><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="4.9     Overdose"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">4.9     Overdose</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><u><span lang="EN-GB">Treatment</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In the event of overdose, consider standard measures to remove unabsorbed active substance. Symptomatic and supportive treatment is recommended.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is not eliminated by haemodialysis; it is not known if it is eliminated by peritoneal dialysis.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Symptoms</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Based on a multiple dose clinical trial in adults and adolescents, in which up to 45 mg of desloratadine was administered (nine times the clinical dose), no clinically relevant effects were observed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="Paediatric population"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The adverse event profile associated with overdosage, as seen during post‑marketing use, is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="5.       PHARMACOLOGICAL PROPERTIES"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.       PHARMACOLOGICAL PROPERTIES</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="5.1     Pharmacodynamic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.1     Pharmacodynamic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Pharmacotherapeutic group: antihistamines – H<sub>1</sub> antagonist, ATC code: R06A X27</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Mechanism of action</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is a non-sedating, long-acting histamine antagonist with selective peripheral H<sub>1</sub>-receptor antagonist activity. After oral administration, desloratadine selectively blocks peripheral histamine H<sub>1</sub>-receptors because the substance is excluded from entry to the central nervous system.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine has demonstrated antiallergic properties from <i>in</i> <i>vitro</i> studies. These include inhibiting the release of proinflammatory cytokines such as IL-4, IL-6, IL-8, and IL-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule P-selectin on endothelial cells. The clinical relevance of these observations remains to be confirmed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Clinical efficacy and safety</span></u></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Paediatric population</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Efficacy of Aerius oral solution has not been investigated in separate paediatric trials. However, the safety of desloratadine syrup formulation, which contains the same concentration of desloratadine as Aerius oral solution, was demonstrated in three paediatric trials. Children, 1-11 years of age, who were candidates for antihistamine therapy received a daily desloratadine dose of 1.25 mg (1 through 5 years of age) or 2.5 mg (6 through 11 years of age). Treatment was well tolerated as documented by clinical laboratory tests, vital signs, and ECG interval data, including QTc. When given at the recommended doses, the plasma concentrations of desloratadine (see section 5.2) were comparable in the paediatric and adult populations. Thus, since the course of allergic rhinitis/chronic idiopathic urticaria and the profile of desloratadine are similar in adults and paediatric patients, desloratadine efficacy data in adults can be extrapolated to the paediatric population.</span></p><p class="MsoNormal" style="line-height:normal;text-autospace:none"><span lang="EN-GB">Efficacy of Aerius syrup has not been investigated in paediatric trials in children less than 12 years of age.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Adults and adolescents</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed. In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine does not readily penetrate the central nervous system. In controlled clinical trials, at the recommended dose of 5 mg daily for adults and adolescents, there was no excess incidence of somnolence as compared to placebo. Aerius tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials. In a single dose study performed in adults, desloratadine 5 mg did not affect standard measures of flight performance including exacerbation of subjective sleepiness or tasks related to flying.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol-induced impairment in performance or increase in sleepiness. No significant differences were found in the psychomotor test results between desloratadine and placebo groups, whether administered alone or with alcohol. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">No clinically relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate. Aerius<span style="layout-grid-mode:line"> effectively controlled symptoms for 24 hours. </span></span><span lang="EN-GB">The efficacy of Aerius tablets has not been clearly demonstrated in trials with adolescent patients 12 th</span><span lang="EN-GB">rough 17 years of age<span style="layout-grid-mode:line">.</span></span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In addition to the established classifications of seasonal and perennial, allergic rhinitis can alternatively be classified as intermittent allergic rhinitis and persistent allergic rhinitis according to the duration of symptoms. Intermittent allergic rhinitis is defined as the presence of symptoms for less than 4 days per week or for less than 4 weeks. Persistent allergic rhinitis is defined as the presence of symptoms for 4 days or more per week and for more than 4 weeks.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Aerius tablets were effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire. The greatest amelioration was seen in the domains of practical problems and daily activities limited by symptoms.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Chronic idiopathic urticaria was studied as a clinical model for urticarial conditions, since the underlying pathophysiology is similar, regardless of etiology, and because chronic patients can be more easily recruited prospectively. Since histamine release is a causal factor in all urticarial diseases, desloratadine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria, as advised in clinical guidelines.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Aerius was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. In each trial, the effects were sustained over the 24 hour dosing interval. As with other antihistamine trials in chronic idiopathic urticaria, the minority of patients who were identified as non-responsive to antihistamines was excluded. An improvement in pruritus of more than 50 % was observed in 55 % of patients treated with desloratadine compared with 19 % of patients treated with placebo. Treatment with Aerius also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.2     Pharmacokinetic properties"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.2     Pharmacokinetic properties</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><span lang="EN-GB"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Absorption</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine plasma concentrations can be detected within 30 minutes of desloratadine administration in adults and adolescents. Desloratadine is well absorbed with maximum concentration achieved after approximately 3 hours; the terminal phase half-life is approximately 27 hours. The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency. The bioavailability of desloratadine was dose proportional over the range of 5 mg to 20 mg. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In a series of pharmacokinetic and clinical trials, 6 % of the subjects reached a higher concentration of desloratadine. The prevalence of this poor metaboliser phenotype was comparable for adult (6 %) and paediatric subjects 2- to 11-year old (6 %), and greater among Blacks (18 % adult, 16 % paediatric) than Caucasians (2 % adult, 3 % paediatric) in both populations.</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt;layout-grid-mode: line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">In a multiple-dose pharmacokinetic study conducted with the tablet formulation in healthy adult subjects, four subjects were found to be poor metabolisers of desloratadine. These subjects had a C</span><sub><span lang="EN-GB">max</span></sub><span lang="EN-GB" style="layout-grid-mode:line"> concentration about 3-fold higher at approximately 7 hours with a terminal phase half-life of approximately 89 hours.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">Similar pharmacokinetic parameters were observed in a multiple-dose pharmacokinetic study conducted with the syrup formulation in paediatric poor metaboliser subjects 2- to 11-year old diagnosed with allergic rhinitis. The exposure (AUC) to desloratadine was about 6-fold higher and the C</span><sub><span lang="EN-GB">max</span></sub><span lang="EN-GB" style="layout-grid-mode:line"> was about 3 to 4 fold higher at 3-6 hours with a terminal half-life of approximately 120 hours. Exposure was the same in adult and paediatric poor metabolisers when treated with age-appropriate doses. The overall safety profile of these subjects was not different from that of the general population. The effects of desloratadine in poor metabolizers &lt; 2 years of age have not been studied.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In separate single dose studies, at the recommended doses, paediatric patients had comparable AUC and C<sub>max</sub> values of desloratadine to those in adults who received a 5 mg dose of desloratadine syrup.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Distribution</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">Desloratadine is moderately bound (83 % - 87 %) to plasma proteins. There is no evidence of clinically relevant active substance accumulation following once daily adult and adolescent dosing of desloratadine (5 mg to 20 mg) for 14 days. </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent. As Aerius oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Biotransformation</span></u></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal">The enzyme responsible for the metabolism of desloratadine has not been identified yet, and therefore, some interactions with other medicinal products cannot be fully excluded. Desloratadine does not inhibit CYP3A4 <i>in vivo,</i> and <i>in vitro</i> studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein.</span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal; page-break-after:avoid"><u><span lang="EN-GB" style="font-weight:normal">Elimination</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">In a single dose trial using a 7.5 mg dose of desloratadine, there was no effect of food (high-fat, high caloric breakfast) on the disposition of desloratadine.<span style="layout-grid-mode:line"> In another study, grapefruit juice had no effect on the disposition of desloratadine.</span></span></p><p align="left" class="MsoBodyTextIndent" style="text-align:left;line-height:normal"><span lang="EN-GB" style="font-weight:normal"> </span></p><p class="MsoNormal" style="line-height:normal;page-break-after:avoid"><u><span lang="EN-GB">Renally impaired patients</span></u></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">The pharmacokinetics of desloratadine in patients with chronic renal insufficiency (CRI) was compared with that of healthy subjects in one single‑dose study and one multiple dose study. In the single‑dose study, the exposure to desloratadine was approximately 2 and 2.5‑fold greater in subjects with mild to moderate and severe CRI, respectively, than in healthy subjects. In the multiple‑dose study, steady state was reached after Day 11, and compared to healthy subjects the exposure to desloratadine was ~1.5‑fold greater in subjects with mild to moderate CRI and ~2.5‑fold greater in subjects with severe CRI. In both studies, changes in exposure (AUC and C<sub>max</sub>) of desloratadine and 3‑hydroxydesloratadine were not clinically relevant.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="5.3     Preclinical safety data"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">5.3     Preclinical safety data</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Desloratadine is the primary active metabolite of loratadine. Non-clinical studies conducted with desloratadine and loratadine demonstrated that there are no qualitative or quantitative differences in the toxicity profile of desloratadine and loratadine at comparable levels of exposure to desloratadine. </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. The lack of carcinogenic potential was demonstrated in studies conducted with desloratadine and loratadine.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="6.       PHARMACEUTICAL PARTICULARS"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.       PHARMACEUTICAL PARTICULARS</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p>
			</div>
		</text>
		
    	    

			    
		               
<section>
			<title value="6.1     List of excipients"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.1     List of excipients</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoEndnoteText" style="page-break-after:avoid"><span lang="EN-GB" style="font-size:11.0pt;layout-grid-mode:line">sorbitol,</span></p><p class="MsoEndnoteText"><span lang="EN-GB" style="font-size:11.0pt;layout-grid-mode: line">propylene glycol,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">sucralose E 955,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">hypromellose 2910,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">sodium citrate dihydrate,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">natural and artificial flavour (bubblegum),</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">citric acid anhydrous,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">disodium edetate,</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="layout-grid-mode:line">purified water</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.2     Incompatibilities"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.2     Incompatibilities</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not applicable.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.3     Shelf life"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.3     Shelf life</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">2 years</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.4     Special precautions for storage"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.4     Special precautions for storage</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Do not freeze. Store in the original package.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.5     Nature and contents of container"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.5     Nature and contents of container</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Aerius oral solution, is supplied in <span style="layout-grid-mode:line">30, 50, 60, 100, 120, 150, 225 and 300 ml</span> size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylene-faced liner. All packages except the 150 ml package are supplied with a measuring spoon marked for doses of 2.5 ml and 5 ml. For the 150 ml package, a measuring spoon or an oral measuring syringe is provided, marked for doses of 2.5 ml and 5 ml.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Not all pack sizes may be marketed.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    

			    
		               
<section>
			<title value="6.6     Special precautions for disposal"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">6.6     Special precautions for disposal</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">No special requirements.</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="7.       MARKETING AUTHORISATION HOLDER"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">7.       MARKETING AUTHORISATION HOLDER</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="EN-GB">Merck Sharp &amp; Dohme B.V.</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">Waarderweg 39</span></p><p class="MsoNormal" style="page-break-after:avoid"><span lang="DE">2031 BN Haarlem</span></p><p class="MsoNormal" style="line-height:normal"><span lang="DE">The Netherlands</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="8.       MARKETING AUTHORISATION NUMBERS "/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">8.       MARKETING AUTHORISATION NUMBERS </span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">EU/1/00/160/061-069</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of first authorisation: </span><span lang="EN-GB">15 January 2001</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB" style="letter-spacing:-.15pt">Date of latest renewal: 15 January 2006</span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB"> </span></p>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
				
			    
						
		               
<section>
			<title value="10.     DATE OF REVISION OF THE TEXT"/>
				<code>
					<coding>
						<system value="http://spor.ema.europa.eu/v1/example-sections"/>
						<code value="${document[n].section[n].subsection[n].typeCode}"/>
						<display value="${document[n].section[n].subsection[n].typeDisplay}"/>
					</coding>
				</code>
		<text>
			<status value="additional"/>
			<div xmlns="http://www.w3.org/1999/xhtml">
		    <p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB">10.     DATE OF REVISION OF THE TEXT</span></b></p><p class="MsoNormal" style="margin-left:28.35pt;text-indent:-28.35pt;line-height: normal;page-break-after:avoid"><b><span lang="EN-GB"> </span></b></p><p class="MsoNormal" style="line-height:normal"><span lang="EN-GB">Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.</span></p><span lang="EN-GB" style='font-size:11.0pt;font-family:"Times New Roman",serif'><br clear="all" style="page-break-before:always"/> </span>
			</div>
		</text>
		
    	    
		
</section>
			    
    	    
		
	
</section>
							<!-- sections can repeat as necessary -->
						</Composition>
					</resource>
				</entry>
				
			</Bundle>
		</resource>
	</entry>
</Bundle>